Phaseline

Companies › Astellas

Astellas: clinical trials, targets and expected readouts

28 active drug programs in 134 registered trials: 56 Phase 2, 43 Phase 1, 23 Phase 3, 12 Phase 4; Oncology, Neurology, Ophthalmology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Enfortumab Vedotin
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 4Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer …Dec 2026
Avacincaptad Pegol Sodium (ASP3021)
Complement C5 inhibitor
C5Phase 4Geographic AtrophyJun 2027
zolbetuximab
Claudin-18 binding agent
CLDN18Phase 3Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Pancreatic Cancer; Pharmacokinetics of Zolbetuximab; Metastatic Pancreatic Adenocarcinoma …Dec 2026
fezolinetant
Neurokinin 3 receptor antagonist
TACR3Phase 3Hot Flashes; Prostate Cancer; Prostate CA; Vasomotor Symptoms …Apr 2027
Setidegrasib (ASP3082)
KRAS G12D inhibitor
KRASPhase 3Pancreatic Cancer; Non-small Cell Lung Cancer (NSCLC); Healthy VolunteerMay 2027
Roxadustat
Hypoxia-inducible factor prolyl hydroxylase inhibitor
EGLN2, P4HTM, EGLN1, EGLN3Phase 3Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic …Oct 2027
ASP2138
Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells
CD3E, CLDN18Phase 3Gastric Adenocarcinoma; Pancreatic Ductal AdenocarcinomaJan 2028
Fezolinetant
Neurokinin 3 receptor antagonist
TACR3Phase 3Hot FlashesMar 2028
Enzalutamide
Androgen Receptor antagonist
ARPhase 3Metastatic Hormone Sensitive Prostate CancerDec 2028
mirabegron
Beta-3 adrenergic receptor agonist
ADRB3Phase 3Neurogenic Detrusor Overactivity; Overactive Bladder Syndrome; Effect of Drug; Urinary Bladder, Overactive …–
ASP5541
CYP17A1 inhibitor (17α-hydroxylase/17,20-lyase inhibitor); intramuscular depot formulation
CYP17A1Phase 2Prostate CancerOct 2028
enzalutamide
Androgen Receptor antagonist
ARPhase 2Prostate CancerJul 2029
Resamirigene bilparvovec (AT132)
AAV8 vector containing a functional copy of the human MTM1 gene
MTM1Phase 2X-Linked Myotubular MyopathyMar 2030
ASP546C (XNW27011)
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 1Pancreatic Adenocarcinoma Metastatic; Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaDec 2026
ASP2390
House dust mite immunotherapy
–Phase 1Allergic to House Dust MitesDec 2026
VIR-5500 (AMX-500)–Phase 1Hormone-refractory Prostate CancerSep 2027
ASP2957
AAV gene therapy delivering MTM1 gene with MHCK7 promoter and MyoAAV3.8 engineered capsid
MTM1Phase 1X-Linked Myotubular MyopathyOct 2027
ASP7317
Retinal pigment epithelium (RPE) cells derived from human pluripotent stem cells
–Phase 1Age-Related Macular DegenerationDec 2027
Gilteritinib
Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor
FLT3, AXLPhase 1Acute Myeloid Leukemia (AML); Non-small Cell Lung Cancer (NSCLC); AML (Acute Myeloid Leukemia); Acute Myeloid Leukemia …Jul 2028
ASP5834
KRAS mutant inhibitor
KRASPhase 1Solid TumorNov 2028
PRL-02 injection
Abiraterone decanoate - CYP17A1 inhibitor for testosterone reduction
CYP17A1Phase 1Prostate CancerMay 2029
ASP2998
anti-TROP2 antibody-drug conjugate
TROP2Phase 1Locally Advanced or Metastatic Malignant Solid TumorsJun 2029
ASP2020
Gene therapy for macular dystrophy
–Phase 1Stargardt DiseaseSep 2029
ASP2246–Phase 1Chronic Ischemic StrokeFeb 2030
ASP388B–Phase 1Locally Advanced or Metastatic Solid TumorsFeb 2030
ASP1002
Anti-CLDN4 antibody-drug conjugate
CLDN4Phase 1Advanced Solid TumorsApr 2030
ASP2767
Gene therapy using harmless viral vector to deliver genes that promote neuroprotective pro
–Phase 1GlaucomaJul 2030
zocaglusagene nuzaparvovec (AT845)
AAV8 vector delivering functional human GAA gene under muscle-specific promoter
GAAPhase 1Pompe Disease (Late-onset)Feb 2035

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05915351Enfortumab VedotinPhase 2Pancreatic Ductal AdenocarcinomaOncologyJun 2025
NCT06903559RoxadustatPhase 1Kidney Failure, ChronicGenitourinaryOct 2025
NCT06917950RoxadustatPhase 1Kidney Failure,ChronicPsychiatryOct 2025
NCT07199894mirabegronPhase 3Nocturnal Enuresis in ChildrenPsychiatryDec 2025
NCT05621616mirabegronPhase 3Neurogenic Detrusor OveractivityGenitourinaryFeb 2026
NCT07773129Setidegrasib (ASP3082)Phase 1Healthy VolunteerOtherOct 2026
NCT03816163zolbetuximabPhase 2Pancreatic CancerOncologyOct 2026
NCT07398261mirabegronPhase 3Treatment of Non-monosymptomatic Nocturnal EnuresisPsychiatryNov 2026
NCT06772272RoxadustatPhase 3Perioperative AnemiaHematologyNov 2026
NCT04963153Enfortumab VedotinPhase 1Locally Advanced Bladder Urothelial CarcinomaOncologyDec 2026
NCT07712848GilteritinibPhase 3AML (Acute Myeloid Leukemia)OncologyDec 2026
NCT05756569Enfortumab VedotinPhase 2Bladder Squamous Cell CarcinomaOncologyDec 2026
NCT06792435ASP546C (XNW27011)Phase 1Pancreatic Adenocarcinoma MetastaticOncologyDec 2026
NCT05221021mirabegronPhase 4Overactive Bladder SyndromeGenitourinaryDec 2026
NCT06396091zolbetuximabPhase 1Metastatic Pancreatic AdenocarcinomaOncologyDec 2026
NCT06862219Enfortumab VedotinPhase 4Metastatic Urothelial CarcinomaOncologyDec 2026
NCT05010772GilteritinibPhase 1Acute Myeloid LeukemiaOncologyDec 2026
NCT04184895ASP2390Phase 1Allergic to House Dust MitesImmunologyDec 2026
NCT06479720mirabegronPhase 4Effect of DrugGenitourinaryDec 2026
NCT05968885mirabegronPhase 4Urinary Bladder, OveractiveGenitourinaryDec 2026
NCT06803030mirabegronPhase 3Ureteral Stent-Related SymptomOtherDec 2026
NCT05775471Enfortumab VedotinPhase 2Renal Pelvis and Ureter Urothelial CarcinomaOncologyJan 2027
NCT06904573Enfortumab VedotinPhase 2Advanced Urothelial CarcinomaOncologyJan 2027
NCT06972875fezolinetantPhase 2Prostate CAOncologyJan 2027
NCT04754191Enfortumab VedotinPhase 2Metastatic Castration-resistant Prostate CancerOncologyJan 2027
NCT05051436mirabegronPhase 4Pre-diabetesMetabolic and endocrineJan 2027
NCT06222580GilteritinibPhase 1Acute Myeloid Leukemia With FLT3/ITD MutationOncologyJan 2027
NCT04724018Enfortumab VedotinPhase 1Urothelial CancerOncologyFeb 2027
NCT05024552GilteritinibPhase 1Acute Myeloid Leukemia With FLT3/ITD MutationOncologyFeb 2027
NCT06891560Enfortumab VedotinPhase 2Adenoid Cystic CarcinomaOncologyMar 2027
NCT03504397zolbetuximabPhase 3Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerOncologyMar 2027
NCT03653507zolbetuximabPhase 3Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerOncologyMar 2027
NCT04225117Enfortumab VedotinPhase 2Locally Advanced or Metastatic Malignant Solid TumorsOncologyMar 2027
NCT05604222mirabegronPhase 4Urgency Urinary IncontinenceGenitourinaryMar 2027
NCT07647289Enfortumab VedotinPhase 2Muscle-Invasive Bladder Cancer (MIBC)OncologyApr 2027
NCT05756777GilteritinibPhase 1Acute Myeloid Leukemia (AML)OncologyApr 2027
NCT07783282fezolinetantPhase 1Prostate CancerOncologyApr 2027
NCT07395024Setidegrasib (ASP3082)Phase 1Healthy VolunteerOtherMay 2027
NCT06225427GilteritinibPhase 1Lung Non-Small Cell CarcinomaOncologyMay 2027
NCT05868265Enfortumab VedotinPhase 2Urothelial CarcinomaOncologyJun 2027
NCT05239624Enfortumab VedotinPhase 2Urothelial CarcinomaOncologyJun 2027
NCT06906822Enfortumab VedotinPhase 2MelanomaOncologyJun 2027
NCT04666636mirabegronPhase 2PreDiabetesMetabolic and endocrineJun 2027
NCT03505320zolbetuximabPhase 2Pharmacokinetics of ZolbetuximabOncologyJun 2027
NCT06970665Avacincaptad Pegol Sodium (ASP3021)Phase 4Geographic AtrophyOphthalmologyJun 2027
NCT05369351mirabegronPhase 2Intracerebral HaemorrhageNeurologyAug 2027
NCT06434350Enfortumab VedotinPhase 1Advanced Bladder CancerOncologySep 2027
NCT05879653Enfortumab VedotinPhase 2Bladder CancerOncologySep 2027
NCT05997615VIR-5500 (AMX-500)Phase 1Hormone-refractory Prostate CancerOncologySep 2027
NCT06041503Enfortumab VedotinPhase 2Adenocarcinoma of the BladderOncologyOct 2027
NCT06235801GilteritinibPhase 1Myeloid LeukemiaOncologyOct 2027
NCT06551246mirabegronPhase 3Urinary Incontinence in ChildrenGenitourinaryOct 2027
NCT06302569Enfortumab VedotinPhase 2Bellini CarcinomaOncologyOct 2027
NCT06022003GilteritinibPhase 2AML, AdultOncologyOct 2027
NCT05970172RoxadustatPhase 3Chronic Kidney DiseaseGenitourinaryOct 2027
NCT07052929ASP2957Phase 1X-Linked Myotubular MyopathyNeurologyOct 2027
NCT04878029Enfortumab VedotinPhase 1Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationOncologyNov 2027
NCT06809140Enfortumab VedotinPhase 2Muscle Invasive Bladder Urothelial CarcinomaOncologyNov 2027
NCT07475806Enfortumab VedotinPhase 2Muscle-invasive Bladder CancerOncologyNov 2027
NCT07139977Enfortumab VedotinPhase 2Endometrial CancerOncologyNov 2027

The 60 nearest readouts of 134 trials; the rest in the app.

From the company's SEC filings

Complete response letters from FDA

Targets

CLDN18 (3) KRAS (2) MTM1 (2) TACR3 (2) CYP17A1 (2) AR (2) GAA (1) TROP2 (1) EGLN2 (1) P4HTM (1) EGLN1 (1) EGLN3 (1)

Companies with the same targets

Revolution Medicines AstraZeneca Novartis Roche Johnson & Johnson (Janssen) Qilu Pharmaceutical TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Bayer Jiangsu HengRui Medicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.